Highest-materiality recent filing
DSS enters $1M loan with related party Alset; note convertible at $0.45, warrants at $0.50
$1M loan from Alset (related party under common control of Chairman Chan Heng Fai).
DSS enters $2.45M convertible note and warrant deal with related party Alset International
Loan of $2,450,000 via convertible promissory note at 3% simple interest.
DSS prices and closes $1.0M underwritten public offering; net proceeds ~$0.7M
Offering of 900,000 shares of common stock at $1.00/share for gross proceeds of $1.0M; closed Feb 5, 2026.
DSS shareholders elect directors, ratify auditor, approve say-on-pay at 2025 meeting
All seven director nominees elected: Ambrose Chan Heng Fai, José Escudero, Lim Sheng Hon Danny, Wai Leung William Wu, Tung Moe Chan, Hiu Pan Joanne Wong, Shui Yeung Frankie Wong.
DSS converts $12M Impact Biomedical debt into 31.9M shares of Impact common stock
DSS settled all outstanding debt owed by Impact Biomedical under a $12M original note and amendments.
DSS replaces auditor Grassi & Co. with HTL International; no disagreements reported
Dismissed Grassi & Co., CPAs, P.C. as independent auditor on June 27, 2025.
DSS grants 1M shares to director's affiliated company as bonus compensation
Board approved issuance of 1,000,000 shares of common stock to Heng Fai Holdings Limited, owned by Director Heng Fai Ambrose Chan, as a bonus for services rendered.
DSS subsidiary invests $1M in True Partner Capital; DSS sells $200K of own stock
Subsidiary True Partner International invested HK$7.8M (~$1M) for 19.5M shares in True Partner Capital Holding at HK$0.40/share.
DSS, Inc. raises ~$1M via private placement of 1,025,746 shares at $0.9749/share
Sold 820,597 shares to Alset Inc. and 205,149 shares to Heng Fai Ambrose Chan at $0.9749 per share.
DSS stockholders elect all seven director nominees and ratify auditor at 2024 annual meeting
All seven director nominees elected; broker non-votes of 1,079,704 on each.
DSS restates 2023 10-K; $23.5M overstatement of deconsolidation loss, discontinued ops omitted
Audit Committee determined 2023 10-K financials unreliable due to errors; restated via 10-K/A filed Oct 22, 2024.
DSS CEO Frank Heuszel steps down; COO Jason Grady named Interim CEO effective Aug 23, 2024
CEO Frank Heuszel resigns effective Aug 23, 2024; remains on American Medical REIT board.
CEO Frank Heuszel to step down; Jason Grady appointed interim CEO
Frank Heuszel resigns as CEO effective Aug 23, 2024; no disagreement with company on operations, policies, or practices.
DSS director Sassuan Samson Lee resigns from board effective Feb 8, 2024
Sassuan Samson (Sam) Lee resigned as a member of the Board of Directors of DSS, Inc. effective immediately on February 8, 2024.
DSS amends $12.86M promissory note with Impact BioMedical, extends maturity to 2030
Principal balance funded to $12,859,328.60, including $1,231,483.14 interest funding advanced Jan 17, 2024.
DSS Inc. effects 1-for-20 reverse stock split, reducing shares from 140M to ~7M
Reverse stock split at 1-for-20 ratio effective January 4, 2024; begins split-adjusted trading Jan 5.
DSS CEO, COO, CFO sign month-to-month interim agreements as prior contracts expire
CEO Frank Heuszel agrees to month-to-month role starting Jan 1, 2024, base salary $260K/yr, no bonus.
DSS stockholders elect all eight director nominees, ratify auditor, approve exec comp
All eight director nominees elected; highest votes for Sassuan Samson Lee (87.6M for, 1.4M against).
DSS receives NYSE American low-price delisting notice; must cure by Apr 20, 2024
Received letter from NYSE American on Oct 20, 2023, citing low share price for substantial period.
DSS, Inc. elects Danny Lim Sheng Hon to Board of Directors, effective Oct 2, 2023
Danny Lim, age 31, elected to DSS Board effective October 2, 2023.
Director John 'JT' Thatch resigns from DSS board effective Aug 31, 2023
John 'JT' Thatch resigned as a director of DSS, effective August 31, 2023.
DSS subsidiary settles $540k interest on SHRG note with 28.9M shares
Second Letter Agreement dated April 17, 2023 between DSSI and SHRG settles interest from Jan 1 to Mar 31, 2023.
DSS settles Maiden Biosciences lawsuit for $8.75M; case dismissed with prejudice
Settlement payment of $8,750,000 made on February 10, 2023.
DSS and affiliates face $14.2M judgment in Maiden lawsuit; intends to appeal
Jury verdict for Maiden; judgment entered Dec 20, 2022: principal $4.24M, prejudgment interest $514,735, post-judgment interest $146,810, plus costs and fees.
DSS reports annual meeting results; all director nominees elected, auditor ratified
Stockholders voted to elect 9 directors: Ambrose Chan Heng Fai, John Thatch, José Escudero, and others.
DSS replaces auditor with Grassi & Co.; reports ongoing internal control deficiencies
Board approved replacing Turner, Stone & Company with Grassi & Co. CPAs, P.C., effective July 1, 2022.
DSS receives NYSE American notice for late Form 10-Q filing; faces potential delisting
Received NYSE American notice on Aug 23, 2022 for failing to timely file Q2 2022 Form 10-Q.
DSS, Inc. will restate FY2021 financials due to $2.1M inventory overstatement
Audit Committee determines FY2021 financial statements cannot be relied upon; restatement of 10-K planned.
DSS issues 21.4M shares to acquire $8.72M convertible note from affiliate
DSS issued 21,366,177 shares of common stock to acquire a convertible note from Alset International Limited (AI), an affiliate.
DSS, Inc. appoints two independent directors: Wong Shui Yeung and Joanne Wong Hiu Pan
Wong Shui Yeung elected independent director effective July 8, 2022; serves on Audit and Nominating/Governance Committees.
On July 7, 2022, DSS issued 17,570,948 shares to Alset EHome International Inc. (AEI) as part of the True Partner Transaction.
DSS increases authorized common shares to 500M; reduces quorum requirement to 35%
Charter amendment raises authorized common stock from 200M to 500M shares, effective June 2, 2022.
DSS issues 15.4M shares to CEO Chan as salary and bonus payment
Issued 15,389,995 shares of common stock to CEO Heng Fai Ambrose Chan on May 25, 2022.
Approved issuance of up to 17.6M shares to Alset EHome International and 21.4M shares to Alset International.
DSS files pro forma financials for $3M SHRG investment, 59.6% stake
DSS invested $3M in SHRG for 50M Class A shares and warrants exercisable at $0.063/share.
DSS reduces AEI share purchase to $1.5M; agrees to acquire 62.1M True Partner shares
DSS amended Jan 25 SPA with AEI: AEI to buy 3,986,877 shares for $1,519,000, down from 44,619,423 shares for $17M.
DSS to acquire convertible promissory note from Alset for $8.7M payable in 21.4M shares
DSS to purchase an $8.35M principal note (plus $367,400 accrued interest) issued by American Medical REIT, Inc.
DSS agrees to sell up to 44.6M shares at $0.381/share for $17M to Alset EHome
Up to 44,619,423 shares of common stock at $0.3810 per share.
DSS issues ~71.4M shares to acquire 25.1% of Alset Intl and True Partner Capital with $1.7B AUM
DSS issued 59,979,582 shares for 877,248,065 ordinary shares of Alset International Limited (25.1% stake).
DSS subsidiary invests $3M in SHRG, acquires 59.6% ownership through shares and warrants
DSS subsidiary Decentralized to invest $3,000,000 for 50M SHRG common shares and 50M warrants at $0.063/share.
Freed Maxick CPAs, P.C. resigned as independent auditor on Dec 2, 2021; Turner, Stone & Company, L.L.P. engaged on Dec 3, 2021.
DSS invests up to $40M in American Pacific Bancorp; APB posts $336K net loss for FY2020
DSS signed SPA to invest up to $40,000,200 for 6,666,700 Class A shares of APB at ~$6.00/share.
DSS subsidiary AMRE acquires three hospitals for $62M; loans $14.7M to fund deal
AMRE acquired hospitals in Fort Worth, TX; Plano, TX; and Pittsburgh, PA for $62 million aggregate.
DSS receives $15M from Alset, invests $40M in American Pacific Bancorp to become majority owner
DSS issues 12,155,591 shares to Alset EHome at $1.234/share for $15M investment.
Board member Lo Wah Wai resigns due to workload, effective August 20, 2021
Lo Wah Wai resigned from Board of Directors effective August 20, 2021.
Document Security Systems appoints Todd Macko as permanent CFO; director compensation plan amended
Todd Macko appointed CFO on Aug 16, 2021; previously Interim CFO since Oct 28, 2020.
DSS acquisition of HWH World terminated after term sheet expired without definitive agreement
Binding term sheet announced January 6, 2021, to acquire all equity of South Korea's HWH World.
Mr. Frank D. Heuszel, announced that effective on the close of business on August 23, 2024, he will step down as the Chief Executive Officer
Effective August 23, 2024, the Board of Directors of DSS, Inc. elected Mr. Jason Grady as the Company’s new Interim Chief Executive Officer.
Effective August 23, 2024, the Board of Directors of DSS, Inc. elected Mr. Jason Grady as the Company’s new Interim Chief Executive Officer.
Mr. Frank D. Heuszel, announced that effective on the close of business on August 23, 2024, he will step down as the Chief Executive Officer of DSS.
On February 8, 2024, Sassuan Samson (Sam) Lee notified DSS, Inc. (the “Company”) that he was resigning as a member of the Board of Directors of the Company, effective immediately.
Effective October 2, 2023, the Board of Directors of DSS, Inc. (“DSS” or the “Company”) elected Mr. Danny Lim Sheng Hon, age 31, as a member of the Company’s Board of Directors (the “Board”).
On September 1, 2023, John “JT” Thatch notified DSS, Inc. (the “Company”) that he was resigning as a member of the Board of Directors of the Company, effective August 31, 2023.
Effective July 11, 2022, the Board of the Company elected Ms. Joanne Wong Hiu Pan as an independent, non-executive director of the Board.
Effective July 8, 2022, the Board of Directors of DSS, Inc. (“DSS” or the “Company”) elected Mr. Wong Shui Yeung as a non-executive member of the Company’s Board of Directors (the “Board”).
On August 19, 2021, Lo Wah Wai resigned as a member of the Board of Directors (“Board”) of Document Security Systems, Inc. (the “Company”).
On August 16, 2021, Document Security Systems, Inc. (“DSS” or the “Company”) appointed Mr. Todd Macko as the Chief Financial Officer of the Company.
Max materiality 0.90 · Median 0.55 · Most common event other_material